Head-To-Head Analysis: Protagonist Therapeutics (PTGX) and The Competition

Protagonist Therapeutics (NASDAQ: PTGX) is one of 190 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Protagonist Therapeutics to similar companies based on the strength of its risk, profitability, valuation, earnings, analyst recommendations, dividends and institutional ownership.


This table compares Protagonist Therapeutics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Protagonist Therapeutics N/A -64.21% -50.51%
Protagonist Therapeutics Competitors -3,824.07% -111.05% -39.39%

Institutional & Insider Ownership

39.7% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 48.2% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 14.3% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Protagonist Therapeutics and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics 0 0 2 0 3.00
Protagonist Therapeutics Competitors 504 2421 6564 122 2.66

Protagonist Therapeutics currently has a consensus target price of $39.50, indicating a potential upside of 138.38%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.73%. Given Protagonist Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Protagonist Therapeutics is more favorable than its peers.

Volatility & Risk

Protagonist Therapeutics has a beta of -3.13, suggesting that its stock price is 413% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics’ peers have a beta of 1.52, suggesting that their average stock price is 52% more volatile than the S&P 500.

Valuation & Earnings

This table compares Protagonist Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Protagonist Therapeutics N/A -$37.17 million -6.16
Protagonist Therapeutics Competitors $215.15 million -$38.89 million -68.29

Protagonist Therapeutics’ peers have higher revenue, but lower earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn’s disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.

Receive News & Ratings for Protagonist Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply